Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel
- PMID: 18241962
- DOI: 10.1016/j.vaccine.2007.12.021
Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel
Abstract
Intestinal immunity was studied in a polio-free community immunised with a combined enhanced inactivated/oral polio vaccine (EIPV/OPV) vaccination programme. Poliovirus excretion was evaluated in three groups of infants primed with a partial (2 EIPV+2 OPV) or complete (3 EIPV+3 OPV) dose schedule. Poliovirus replicated in the gut of 59.8-55.8% of infants in the three groups 7 days after administration of an additional OPV dose. Significant decreases in the percent of type-specific-virus excreters appeared after 14 and 21 days for serotypes 1 and 2, and after 21 and 28 days for serotype 3. The percent of excreters was inversely correlated with pre-challenge neutralising antibody (NA) titers (p<0.05). Intrafamilial virus transmission to mothers and siblings was minimal. The principal factor for interruption of disease and virus transmission in the community was a strong and persistent humoral immunity with immunological memory. A satisfactory level of family hygiene contributed towards breaking the chain of transmission of poliovirus to contacts.
Similar articles
-
Anomalous observations on IPV and OPV vaccination.Dev Biol (Basel). 2001;105:197-208. Dev Biol (Basel). 2001. PMID: 11763328
-
Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis.Vaccine. 1998 Dec;16(20):2090-5. doi: 10.1016/s0264-410x(98)00071-1. Vaccine. 1998. PMID: 9796069
-
Oral poliovaccine: will it help eradicate polio or cause the next epidemic?Isr Med Assoc J. 2006 May;8(5):312-5. Isr Med Assoc J. 2006. PMID: 16805227
-
Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis.Lancet Infect Dis. 2019 Oct;19(10):1121-1128. doi: 10.1016/S1473-3099(19)30301-9. Epub 2019 Jul 23. Lancet Infect Dis. 2019. PMID: 31350192
-
Global eradication of poliomyelitis: reinvent the wheel or use existing options effectively?Public Health Rev. 1993-1994;21(1-2):143-50. Public Health Rev. 1993. PMID: 8041881 Review.
Cited by
-
Expert review on poliovirus immunity and transmission.Risk Anal. 2013 Apr;33(4):544-605. doi: 10.1111/j.1539-6924.2012.01864.x. Epub 2012 Jul 15. Risk Anal. 2013. PMID: 22804479 Free PMC article. Review.
-
Cutting-edge research frontiers in oral cavity vaccines for respiratory diseases: a roadmap for scientific advancement.Front Cell Infect Microbiol. 2024 Jun 26;14:1388222. doi: 10.3389/fcimb.2024.1388222. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38988815 Free PMC article. Review.
-
Relationship Between Helicobacter pylori IgG Seroprevalence and the Immune Response to Poliovirus Vaccine Among School-Age Children From a Population With Near-Universal Immunity Level.Front Med (Lausanne). 2022 Jan 20;8:797719. doi: 10.3389/fmed.2021.797719. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35127752 Free PMC article.
-
Inferring Numbers of Wild Poliovirus Excretors Using Quantitative Environmental Surveillance.Vaccines (Basel). 2021 Aug 6;9(8):870. doi: 10.3390/vaccines9080870. Vaccines (Basel). 2021. PMID: 34451995 Free PMC article.
-
The Duration of Intestinal Immunity After an Inactivated Poliovirus Vaccine Booster Dose in Children Immunized With Oral Vaccine: A Randomized Controlled Trial.J Infect Dis. 2017 Feb 15;215(4):529-536. doi: 10.1093/infdis/jiw595. J Infect Dis. 2017. PMID: 28003352 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical